Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains how the Biologics Price Competition and Innovation Act (BPCIA) has impacted the industry.
Transcript:
I think it's certainly the changes and the new regulatory pathway has certainly helped us as an industry continue to refine and move forward. I think there's some definite advantages for biosimilars in terms of what those hurdles actually are from a safety and efficacy perspective without at all compromising patient safety or what the true requirements are. I mean, the fact that we have to do comparative trials to demonstrate that there's no difference between the efficacy and safety that we have versus an originator across multiple batches, right, is pretty significant, and I think should lend a lot of credibility and confidence to the marketplace.
At the same time, I think we're still learning, right? So, from a drug development perspective, when you're looking at these kinds of investments, which are significant, I mean, we're running clinical trials like an originator would, I think that we're looking at things like how do we use extrapolation or do we have to do these trials around interchangeability that I think the FDA's still working on. How are we going to overcome some of those kinds of challenges?
And especially for the United States to be able to benefit from the simplicity of the European system, I think those are some of the things that we think could certainly add a great deal of policy information to speed along some of those changes. But for sure the openness in Washington right now to working with our industry to making sure that it's not a standard generic. It's not pill pressing. It is a biologic that requires the right kind of hurdles in order to make sure. And manufacturing these things, not easy, right? It's a very difficult process, and we take it very seriously. I think for Sandoz we're really lucky, because we have the benefit of our parent company as well as our own 35 years' worth of experience in this area. So we're certainly leveraging all of that, and then the openness to work with government in order to make it as smooth and as robust as we possibly can. So we're excited about the changes that have happened in the United States.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Top 5 Most-Read Legal Articles of 2024
December 23rd 2024The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and addressing challenges like litigation, regulatory hurdles, and patent disputes that shape the competitive landscape of affordable biologics.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.